


WHAT IS CLAIMED IS:

1. A crystalline salt form of Compound (1)



2. The crystalline salt form according to claim 1, wherein the crystalline salt form is a hydrochloride, oxalate, maleate, sulfate, or mesylate salt.
3. The crystalline salt form according to claim 1, wherein the crystalline salt form is a hydrochloride salt having an X-ray powder diffraction pattern comprising peaks at approximately 9.7, 10.1, 14.3, 15.0, 17.5, 18.9, 21.9, and 23.7 degrees 2θ .
4. The crystalline salt form according to claim 1, wherein the crystalline salt form is a hydrochloride salt having a differential scanning calorimetry thermogram endotherm T_{onset} at approximately 252 °C and an X-ray powder diffraction pattern comprising peaks at approximately 9.7, 10.1, 14.3, 15.0, 17.5, 18.9, 21.9, and 23.7 degrees 2θ .
5. The crystalline salt form according to claim 1, wherein the crystalline salt form is a oxalate salt having an X-ray powder diffraction pattern comprising peaks at approximately 11.7, 13.0, 15.4, 16.3, 19.6, 22.1, and 24.5 degrees 2θ .
6. The crystalline salt form according to claim 1, wherein the crystalline salt form is a oxalate salt having a differential scanning calorimetry thermogram endotherm T_{onset} at approximately 205 °C and an X-ray powder diffraction pattern comprising peaks at approximately 11.7, 13.0, 15.4, 16.3, 19.6, 22.1, and 24.5 degrees 2θ .

7. The crystalline salt form according to claim 1, wherein the crystalline salt form is a maleate salt having an X-ray powder diffraction pattern comprising peaks at approximately 8.0, 10.4, 12.4, 14.0, 15.3, 16.4, 19.3, 21.5, and 23.3 degrees 2θ .
- 5
8. The crystalline salt form according to claim 1, wherein the crystalline salt form is a maleate salt having a differential scanning calorimetry thermogram endotherm T_{onset} at approximately 193 °C and an X-ray powder diffraction pattern comprising peaks at approximately 8.0, 10.4, 12.4, 14.0, 15.3, 16.4, 19.3, 21.5, and 23.3 degrees 2θ .
- 10
9. The crystalline salt form according to claim 1, wherein the crystalline salt form is a sulfate salt having an X-ray powder diffraction pattern comprising peaks at approximately 8.4, 12.6, 13.7, 16.7, 21.0, 21.8, 22.2, and 23.4 degrees 2θ .
- 15
10. The crystalline salt form according to claim 1, wherein the crystalline salt form is a sulfate salt having a differential scanning calorimetry thermogram endotherm T_{onset} at approximately 229 °C and an X-ray powder diffraction pattern comprising peaks at approximately 8.4, 12.6, 13.7, 16.7, 21.0, 21.8, 22.2, and 23.4 degrees 2θ .
- 20
11. The crystalline salt form according to claim 1, wherein the crystalline salt form is a mesylate salt having an X-ray powder diffraction pattern comprising peaks at approximately 7.9, 11.3, 12.6, 12.9, 14.7, 16.1, 20.0, and 20.7 degrees 2θ .
- 25
12. The crystalline salt form according to claim 1, wherein the crystalline salt form is a mesylate salt having a differential scanning calorimetry thermogram endotherm T_{onset} at approximately 238 °C and an X-ray powder diffraction pattern comprising peaks at approximately 7.9, 11.3, 12.6, 12.9, 14.7, 16.1, 20.0, and 20.7 degrees 2θ .
- 30
13. A pharmaceutical composition comprising the crystalline salt form of any one of claims 1 to 12, and a pharmaceutically acceptable carrier.

14. The pharmaceutical composition of claim 13, which is a single unit dosage form.
15. The pharmaceutical composition according to claim 13, wherein the crystalline salt
5 form is in substantially pure form.
16. A method of treating chronic pain, anxiety, insomnia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, hepatic steatosis, and metabolic syndrome in a mammal comprising administering to the mammal a therapeutically-effective amount of the
10 pharmaceutical composition according to claims 13 to 15.
17. A method of treating chronic pain, anxiety, insomnia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, hepatic steatosis, and metabolic syndrome in a mammal comprising administering to the mammal a pharmaceutical composition comprising a
15 therapeutically-effective amount of the crystalline salt form according to claims 1 to 12.
18. The method according claim 17, wherein the therapeutically-effective amount of the crystalline salt form is about 5 mg to about 500 mg.